Trial Profile
A Phase II Study of the Association of Glivec (Imatinib Mesylate, Formerly Known as STI 571) Plus Gemzar (Gemcitabine) in Patients With Unresectable, Refractory, Malignant Mesothelioma Expressing Either PDGFR-Beta [platelet derived growth factor receptor-beta] or C-Kit
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Imatinib (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- 14 Nov 2007 New trial record.